Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of cimetidine on survival after gastric cancer

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Tønnesen, H, Knigge, U, Bülow, S, Damm, P, Fischerman, K, Hesselfeldt, P, Hjortrup, A, Pedersen, IK, Pedersen, VM & Siemssen, OJ 1988, 'Effect of cimetidine on survival after gastric cancer' Lancet, vol. 2, no. 8618, pp. 990-992.

APA

Tønnesen, H., Knigge, U., Bülow, S., Damm, P., Fischerman, K., Hesselfeldt, P., ... Siemssen, O. J. (1988). Effect of cimetidine on survival after gastric cancer. Lancet, 2(8618), 990-992.

CBE

Tønnesen H, Knigge U, Bülow S, Damm P, Fischerman K, Hesselfeldt P, Hjortrup A, Pedersen IK, Pedersen VM, Siemssen OJ. 1988. Effect of cimetidine on survival after gastric cancer. Lancet. 2(8618):990-992.

MLA

Tønnesen, H et al. "Effect of cimetidine on survival after gastric cancer". Lancet. 1988, 2(8618). 990-992.

Vancouver

Tønnesen H, Knigge U, Bülow S, Damm P, Fischerman K, Hesselfeldt P et al. Effect of cimetidine on survival after gastric cancer. Lancet. 1988 Oct 29;2(8618):990-992.

Author

Tønnesen, H ; Knigge, U ; Bülow, Steffen ; Damm, P ; Fischerman, K ; Hesselfeldt, Peter ; Hjortrup, A ; Pedersen, I K ; Pedersen, V M ; Siemssen, O J. / Effect of cimetidine on survival after gastric cancer. In: Lancet. 1988 ; Vol. 2, No. 8618. pp. 990-992.

Bibtex

@article{11a435a397874c00907cd1995bcf0d33,
title = "Effect of cimetidine on survival after gastric cancer",
abstract = "The effect of cimetidine on survival was investigated in 181 patients with gastric cancer. Immediately after operation or the decision not to operate, the patients were randomised in double-blind fashion to placebo or cimetidine 400 mg twice daily for two years or until death, with review every three months. Median survival in the cimetidine group was 450 days (range 1-1826) and in the placebo group 316 days (1-1653). The relative survival rates (cimetidine/placebo) were 45{\%}/28{\%} at 1 year, 22{\%}/13{\%} at 2 years, 13{\%}/7{\%} at 3 years, 9{\%}/3{\%} at 4 years, and 2{\%}/0{\%} at 5 years. Survival in the cimetidine group was significantly longer than in the placebo group.",
keywords = "Actuarial Analysis, Adult, Aged, Aged, 80 and over, Cimetidine, Clinical Trials as Topic, Denmark, Double-Blind Method, Drug Evaluation, Female, Humans, Male, Middle Aged, Multicenter Studies as Topic, Neoplasm Staging, Prognosis, Prospective Studies, Random Allocation, Retrospective Studies, Stomach Neoplasms, Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial",
author = "H T{\o}nnesen and U Knigge and Steffen B{\"u}low and P Damm and K Fischerman and Peter Hesselfeldt and A Hjortrup and Pedersen, {I K} and Pedersen, {V M} and Siemssen, {O J}",
year = "1988",
month = "10",
day = "29",
language = "English",
volume = "2",
pages = "990--992",
journal = "Lancet",
issn = "0140-6736",
publisher = "The/Lancet Publishing Group",
number = "8618",

}

RIS

TY - JOUR

T1 - Effect of cimetidine on survival after gastric cancer

AU - Tønnesen, H

AU - Knigge, U

AU - Bülow, Steffen

AU - Damm, P

AU - Fischerman, K

AU - Hesselfeldt, Peter

AU - Hjortrup, A

AU - Pedersen, I K

AU - Pedersen, V M

AU - Siemssen, O J

PY - 1988/10/29

Y1 - 1988/10/29

N2 - The effect of cimetidine on survival was investigated in 181 patients with gastric cancer. Immediately after operation or the decision not to operate, the patients were randomised in double-blind fashion to placebo or cimetidine 400 mg twice daily for two years or until death, with review every three months. Median survival in the cimetidine group was 450 days (range 1-1826) and in the placebo group 316 days (1-1653). The relative survival rates (cimetidine/placebo) were 45%/28% at 1 year, 22%/13% at 2 years, 13%/7% at 3 years, 9%/3% at 4 years, and 2%/0% at 5 years. Survival in the cimetidine group was significantly longer than in the placebo group.

AB - The effect of cimetidine on survival was investigated in 181 patients with gastric cancer. Immediately after operation or the decision not to operate, the patients were randomised in double-blind fashion to placebo or cimetidine 400 mg twice daily for two years or until death, with review every three months. Median survival in the cimetidine group was 450 days (range 1-1826) and in the placebo group 316 days (1-1653). The relative survival rates (cimetidine/placebo) were 45%/28% at 1 year, 22%/13% at 2 years, 13%/7% at 3 years, 9%/3% at 4 years, and 2%/0% at 5 years. Survival in the cimetidine group was significantly longer than in the placebo group.

KW - Actuarial Analysis

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Cimetidine

KW - Clinical Trials as Topic

KW - Denmark

KW - Double-Blind Method

KW - Drug Evaluation

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Multicenter Studies as Topic

KW - Neoplasm Staging

KW - Prognosis

KW - Prospective Studies

KW - Random Allocation

KW - Retrospective Studies

KW - Stomach Neoplasms

KW - Clinical Trial

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

M3 - Journal article

VL - 2

SP - 990

EP - 992

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 8618

ER -

ID: 32522129